Sun Pharma Names Kirti Ganorkar as Managing Director in Major Leadership Transition
Kirti Ganorkar, a 29-year Sun Pharma veteran, will become Managing Director on September 1, 2025, succeeding founder Dilip Shanghvi who transitions to Executive Chairman.
Sun Pharma Discontinues Psoriasis and Eczema Drug SCD-044 After Phase 2 Trial Failures
Sun Pharma's experimental oral drug SCD-044 (Vibozilimod) failed to meet primary endpoints in Phase 2 trials for both psoriasis and atopic dermatitis, missing the 75% improvement target in PASI and EASI scores at 16 weeks.
FDA Approves Sun Pharma's Next-Generation LED BLU-U Device for Actinic Keratosis Treatment
The FDA has granted premarket approval for Sun Pharma's next-generation BLU-U Blue Light Photodynamic Therapy Illuminator, featuring LED panels instead of fluorescent tubes for treating actinic keratosis.
Sun Pharma Increases Investment in US-Based Pharmazz to Expand Specialty Therapeutics Portfolio
Sun Pharma has signed an agreement to invest up to $25 million in US-based Pharmazz, increasing its stake to approximately 22.7% on a fully diluted basis.
Sun Pharma and Moebius Medical's MM-II Shows Promising Results for Knee Osteoarthritis in Phase 2b Trial
A single injection of MM-II, a novel non-opioid treatment developed by Sun Pharma and Moebius Medical, demonstrated clinically meaningful pain relief for knee osteoarthritis lasting up to 26 weeks in a Phase 2b trial involving 397 patients.
Sun Pharma Launches Fexuclue in India: A Novel Treatment for Erosive Esophagitis
Sun Pharmaceutical has introduced Fexuclue (fexuprazan 40 mg), a novel potassium-competitive acid blocker, as a new treatment option for adults with all grades of erosive esophagitis in India.
Fortress Biotech Reports Strong 2024 Results with Two FDA Approvals and Strategic Acquisition Deal
Fortress Biotech secured FDA approvals for two key products in Q4 2024: Emrosi for inflammatory lesions of rosacea and UNLOXCYT for advanced cutaneous squamous cell carcinoma, with commercial launch of Emrosi already underway.
Lupin Launches First Generic Xarelto in US Market Despite Ongoing Patent Litigation
Lupin has begun rolling out the first generic version of the blockbuster anticoagulant Xarelto (rivaroxaban) in the US market after the Patent Trial and Appeal Board invalidated a key patent.
Sun Pharma to Acquire Checkpoint Therapeutics in $355 Million Deal for Novel Skin Cancer Treatment
Sun Pharmaceutical Industries will acquire Checkpoint Therapeutics for $355 million upfront, with stockholders receiving $4.10 per share plus a contingent value right worth up to $0.70 per share based on European approval milestones.
Novo Nordisk Plans India Entry for Ozempic Despite Looming Patent Expiry as Indian Pharma Giants Prepare Generic Alternatives
Danish pharmaceutical giant Novo Nordisk confirms readiness to launch its blockbuster GLP-1 drug Semaglutide (Ozempic) in India despite patent expiration in January 2026, emphasizing continued market leadership strategy.